ASTANA, Kazakhstan, April 24. Qazaqstan Investment Corporation (QIC, a subsidiary of Kazakhstan’s Baiterek) and the Singaporean company FCAP Investors Pte. Ltd. announced the creation of the Forebright Life Science Technology Fund, L.P., as one of its primary investors, Trend reports.
"The fund will focus its efforts on research in the fields of multi-omics technologies and synthetic biology (excluding human genetic engineering), including projects related to comprehensive newborn screening services and the prevention and control of congenital diseases," said the message from Qazaqstan Investment Corporation.
A total of $200 million will be invested in the fund. It is planned that the fund will operate until 2035.
The company added that the geographical scope of the fund includes Kazakhstan as well as countries in the Middle East, Europe, and Asia. It is expected that in Kazakhstan, funding will be directed to projects focused on reproductive health and preventive medicine.
The creation of the fund was initiated during the official visit of the President of the Republic of Kazakhstan to Singapore in May 2024.
Qazaqstan Investment Corporation is a fund of funds for direct investments established in 2007, with the main mission of developing direct investments and venture financing in Kazakhstan to support the country's sustainable economic development.
FCAP is a leading Singaporean management company specializing in private equity and venture investments, focusing on the development of innovative technologies and supporting fast-growing businesses. The company actively invests in areas such as biotechnology, pharmaceuticals, healthcare, information technology, and clean technologies.
